MINE方案治疗复发难治性非霍奇金淋巴瘤23例

The Clinical Efficacy of MINE Regimen for the Treatment on 23 Case of Recurrent and Refractory Non Hodgkin’s Lymphoma

目的观察MINE（MIT、VP16、IFO）方案治疗复发及难治性非霍奇金淋巴瘤近期疗效及毒副反应。方法23例经CHOP方案治疗失败的NHL患者接受MINE方案化疗至少2个周期，MIT6～8mg／m^2／d，静滴，d1；IFO 2．0静滴，d1-3，配合美司那400mg／次，0h、4h、8h静推3次；VP1680mg／m^2／d，静滴，d1～3。疗效及毒性判定按照WHO标准。结果完全缓解（CR）5例，部分缓解（PR）10例，稳定（SD）3例，进展（PD）5例，总有效率（CR＋PR）65．2％，毒副反应主要为骨髓抑制，白细胞减少率73．9％，以Ⅰ～Ⅱ度为主。经G-CSF支持后恢复正常，无与毒性相关的死亡发生。结论MINE方案治疗难治性NHL有较高疗效，并较为安全，患者可耐受。

Objective To observe the antitumor effect and toxicities of MINE regimen based on mitoxantron, etoposide, ifosfamide in the patients with recurrent and refractory non-Hodgkin＇ s lymphoma. Methods Total of 23 patients failing to respond to CHOP regimen were treated with MINE regimen and every patient had gotten at least 2 cycles treatment. MIT 6-8mg/m^2/d,Ⅳ on d1;IFO 2. 0 Ⅳ on d1-3, combined with mesna 400mg Ⅳ for 3 times（0h.4h.8h）, d1-3 ;VP16 80mg/m^2/d, Ⅳ on d1-3. The therapeutic effects and toxicity were evaluated according to the WHO criteria. Results In 23 patients, 65.2% of response rate were achieved with 5 case CR, 10 case PR,3 case SD, 5 case PD. Main side-effect was myelosuppression. Neutropenia was reported in 73. 9% of patients and it was mostly Grade Ⅰ / Ⅱ. All of them got G-CSF treatment and the counts of white blood cells became normal. No patient died of toxicity related to chemotherapy. Conclusion MINE regimen has a safe and higher therapeutic effect on resistant patients with NHL.